September 15th 2025
FLAURA2 data show osimertinib plus chemotherapy significantly improves overall survival vs osimertinib alone in frontline EGFR+ advanced NSCLC.
September 12th 2025
Early Study Results Show Novel Combo Therapy May Be Effective in Lung Cancer Subtype
July 14th 2021The preliminary results of an early-phase study of rigosertib combined with nivolumab for the treatment of advanced metastatic KRAS-mutated non-small cell lung cancer are scheduled to be presented at an upcoming medical conference.
FDA Grants Sintilimab/Pemetrexed Review for Frontline Nonsquamous NSCLC
May 19th 2021A biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer has been accepted for FDA review.
Sotorasib Granted Priority Review for KRAS G12C–Mutated Advanced or Metastatic NSCLC
February 17th 2021The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy.
FDA Approves Trilaciclib for Chemo-Induced Bone Marrow Suppression in Small Cell Lung Cancer
February 12th 2021The FDA has approved trilaciclib to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.
Better Care for Minorities, Improved Telehealth: Next Steps in Lung Cancer
February 8th 2021“We should never be complacent; we should never be skeptical,” said Lilenbaum. “We need to continue to pursue new treatments, and if nothing else, the past 2 decades are a testament to how we can actually make a difference in the natural history of the disease by appropriate interventions.”
Pembrolizumab-Ipilimumab Combo Boosts Toxicity, Not Survival in NSCLC
February 7th 2021Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.
Patients Need Better Treatment Education, Study Finds
January 31st 2021Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision, according to results from a study presented at the 2020 World Conference on Lung Cancer Singapore.